Research Analysts Offer Predictions for Harrow Q3 Earnings

Key Points

• B. Riley analysts have raised their Q3 2025 earnings per share (EPS) estimate for Harrow, Inc. from $0.25 to $0.29.
• Harrow has received multiple upgrades from analysts, with a consensus rating of "Buy" and an average target price of $64.67.
• Shares of Harrow opened at $38.16 and have shown significant institutional interest, with 72.76% of the company's stock owned by institutional investors.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Equities researchers at B. Riley upped their Q3 2025 EPS estimates for Harrow in a research note issued to investors on Thursday, August 21st. B. Riley analyst M. Mamtani now forecasts that the company will earn $0.29 per share for the quarter, up from their prior estimate of $0.25. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's Q4 2025 earnings at $0.65 EPS and FY2027 earnings at $4.21 EPS.

Several other equities research analysts have also recently weighed in on the stock. HC Wainwright increased their target price on shares of Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. BTIG Research raised their price objective on shares of Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Zacks Research raised shares of Harrow from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. William Blair began coverage on shares of Harrow in a report on Tuesday, June 10th. They issued an "outperform" rating for the company. Finally, Cantor Fitzgerald initiated coverage on shares of Harrow in a research note on Friday, July 11th. They issued an "overweight" rating and a $76.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $64.67.

Harrow Stock Performance

Shares of NASDAQ HROW traded up $0.01 during mid-day trading on Friday, hitting $38.58. The company had a trading volume of 219,015 shares, compared to its average volume of 482,723. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The business's 50-day simple moving average is $34.21 and its 200-day simple moving average is $29.25. Harrow has a 12 month low of $20.85 and a 12 month high of $59.23. The firm has a market cap of $1.43 billion, a P/E ratio of -154.24 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The firm had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

Institutional Trading of Harrow

Several hedge funds and other institutional investors have recently modified their holdings of HROW. GF Fund Management CO. LTD. bought a new stake in shares of Harrow during the 4th quarter worth approximately $25,000. Quarry LP acquired a new stake in Harrow in the first quarter worth $32,000. Raymond James Financial Inc. bought a new position in shares of Harrow in the second quarter valued at $48,000. Tower Research Capital LLC TRC lifted its position in shares of Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after purchasing an additional 1,462 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Harrow in the fourth quarter worth about $78,000. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.